DAM
CBAY

Doheny Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Doheny Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-41,500
Closed -$212K – 100
2019
Q3 		$212K Sell
41,500
-35,275
-46% -$214K 0.18% 88
2019
Q2 		$550K Buy
76,775
+35,575
+86% +$403K 0.46% 59
2019
Q1 		$547K Buy
+41,200
New +$438K 0.47% 57
2018
Q4 		– Sell
-36,175
Closed -$401K – 100
2018
Q3 		$401K Buy
+36,175
New +$449K 0.21% 82

Other funds holding CBAY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Doheny Asset Management's CBAY Position: Q4 2019 in Review

Doheny Asset Management sold out of Cymabay Therapeutics (CBAY) in Q4 2019, closing a stake of 41,500 shares — an estimated $212K sold.

Doheny Asset Management first reported a position in CBAY in Q3 2018 and held it in 4 quarters. The position peaked at $550K in Q2 2019. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2019.

  • Doheny Asset Management reported no remaining Cymabay Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Doheny Asset Management sold 41,500 Cymabay Therapeutics shares in Q4 2019, an estimated $212K.
  • Doheny Asset Management first reported a position in Cymabay Therapeutics in Q3 2018 and held it in 4 quarters.
  • Doheny Asset Management's Cymabay Therapeutics position peaked at $550K in Q2 2019.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2019.

Based on Doheny Asset Management's 13F filing for Q4 2019, filed 11 Feb 2020.